Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. - Wikidata - wikimedia - TriplyDB

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

http://www.wikidata.org/entity/Q40440656

about

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Targeting CDK6 in cancer: State of the art and new insights Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.Targeting the RB-E2F pathway in breast cancer Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer Emerging links between E2F control and mitochondrial function Targeting CDK4 and CDK6: From Discovery to Therapy CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.Recent advances of highly selective CDK4/6 inhibitors in breast cancer The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition.Probing the probes: fitness factors for small molecule tools.Tailoring to RB: tumour suppressor status and therapeutic response.The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.The history and future of targeting cyclin-dependent kinases in cancer therapy.Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency.A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.The Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21WAF1/CIP1 in 143B Osteosarcoma Cell Growth Arrest.Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy Lenvatinib and Palbociclib.CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.

P2860

Q21195212-05C21345-48A8-4D76-94A0-9BC3AB833E4A Q26796499-10A3C2CA-2F2E-429A-A696-52C53D86AEFA Q26827580-94CCD635-3A6C-47D0-BF1A-32B1932A9F08 Q27677453-D07C8902-9C96-4D1A-881F-AA32A4B27DDE Q27684150-72A2E979-8BA1-4807-8417-E9A91B531FDC Q27851556-AEB7CB94-B414-41AC-90B4-2BC14D7486EB Q27851564-C9064F4B-78CE-4E97-8796-C41715E2777C Q27852177-6A4EE93B-1333-405B-A69B-463F79E5F43F Q28069626-3E029533-45A1-41BF-9A8B-92141B7D6E18 Q28069910-953C048A-5997-49EC-AE2B-210F80B8EA6A Q28072793-4EB10CA5-03C9-4111-B65F-23F09BC17486 Q28082267-12860B03-9135-416B-A2A0-58F56D1433A3 Q28082912-3BFB55FF-6290-418B-B407-4BB23126674C Q28533417-3924B0CC-3B3E-4EE0-949C-DC6F63AF2416 Q28537720-79F699FC-2372-4D02-B6E5-727199855EAC Q30419997-5DB12267-3191-4AD5-95BC-4ECCA4CC456B Q33602076-224E949B-7FFB-4CA3-96E1-D2AC6403C857 Q33638023-E378D688-88E6-4E0A-9B64-DEB9FF6F28CE Q33737298-DC8CAFC9-3FC8-4877-92AD-3AC32F0BFE05 Q33812043-0B35EC7E-F13B-47B5-94FC-BC560CFFA957 Q33968055-DF862F7E-98C3-4894-B0F8-4EEFA84790B8 Q34001269-D3252BDF-0629-48C7-85D1-FB696EC75576 Q34040108-B63E13A2-023B-4F1D-813D-A439EF148E01 Q34115095-7AEDEC96-7D09-4CBB-BB7A-50667C08F9B3 Q34147910-43F1A673-DDB1-4218-8EB4-40DAA89B7AB5 Q34227791-37AFB8FB-45BD-445C-ADE8-7131A302CBE1 Q34335802-E2837ED8-7326-46C2-A77A-5B5596214D76 Q34460347-7BF13A44-2369-47B9-8B91-53ABC047083E Q34487091-617B2076-1E20-4658-98A2-02D3E587DACE Q35034758-0F0AAE52-211F-4DF5-8B9E-E7FE721C7E81 Q35036658-4CD7B44F-D623-412A-A77A-ED11CA3EF395 Q35099578-8A419617-C67D-48A5-87FB-94EECDE7E265 Q35649604-AC479AF0-E2A8-4884-A203-D126E6BDC725 Q35842970-31311B03-1598-4B6F-BBC3-588F21DE0B84 Q35958082-4404873A-574A-4A6A-B7EA-7F928E65E402 Q36010739-17F634A5-E9D1-4A6D-864D-DCA2AB6CCC7F Q36015334-49DAE52B-9203-401C-8051-76478A710647 Q36109982-16A6432B-D8FE-4860-BE25-4866893169B8 Q36130084-265292D1-2E1A-4073-945F-DDDF44B0E6AA Q36189481-FB209C03-821A-4B00-9069-0377C6632BA0

P2860

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

http://www.wikidata.org/entity/Q40440656

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

@en

type

label

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

@en

prefLabel

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

@en

P1433

Q40440656-055F76DF-D80A-4C05-B000-45FDA757F3BC

P1476

Q40440656-44E7802F-95C8-4B6F-B5D1-0EEF0A1CE4C5

P2093

Q40440656-00BBE2C7-3FEA-47C9-BDAD-1DFB136E88F9

Q40440656-05CAB4D5-E64C-49F6-84B9-072E03D24067

Q40440656-16D5E450-BB75-44F8-8761-88454E7A93A3

Q40440656-241CF6A0-5E3C-42A3-84C0-ACA7731F6734

Q40440656-33EDD504-F402-494B-8285-6F1388C6D9EB

Q40440656-3692A761-8B4C-4EBB-9384-E5332AFB24A9

Q40440656-3D5D3717-0431-4568-971C-DF071E9C4A8B

Q40440656-479DF2C6-3629-4ACE-A48B-1B682AECBF70

Q40440656-4CB3F055-08CB-43B5-BC00-03DCA7C98C27

Q40440656-59E8E68D-BDDD-46EA-9862-05A86678A43A

P304

Q40440656-A861D05B-54E1-4E6A-BF3C-76E2989849E5

P31

Q40440656-32239089-5146-4637-8A2E-7938B7677282

P356

Q40440656-365F38B7-F66A-48E0-990A-17C738A04748

P407

Q40440656-A16EF8DD-D74C-4ADE-8D50-2059E6BFD519

P433

Q40440656-06E18FFA-B36B-4B98-BC64-F2CD7A6427B2

P478

Q40440656-5AEAC0CB-3CB0-483C-BB43-4842169AC0F7

P577

Q40440656-BA97647B-9CF5-4D86-9405-9A67E3478A15

P698

Q40440656-A2483932-D8D2-4E2D-969B-7A04F976FF2C

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

@en

P2093

Chung Choi

http://www.w3.org/2001/XMLSchema#string

David W Fry

http://www.w3.org/2001/XMLSchema#string

Debra Sherry

http://www.w3.org/2001/XMLSchema#string

Dennis J McNamara

http://www.w3.org/2001/XMLSchema#string

Derek J Sheehan

http://www.w3.org/2001/XMLSchema#string

Hairong Zhou

http://www.w3.org/2001/XMLSchema#string

Joanne Brodfuehrer

http://www.w3.org/2001/XMLSchema#string

Joseph T Repine

http://www.w3.org/2001/XMLSchema#string

Mark R Barvian

http://www.w3.org/2001/XMLSchema#string

Patricia J Harvey

http://www.w3.org/2001/XMLSchema#string

P304

2388-2406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM049354H

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15801831

http://www.w3.org/2001/XMLSchema#string